Hemodynamic interactions of propofol and dantrolene in chronically instrumented dogs.
The hemodynamic interaction of dantrolene, a specific drug for malignant hyperthermia, and propofol which appears to be safe in malignant hyperthermia-susceptible patients, has not been investigated. We performed this study to examine the hemodynamic actions of dantrolene at a therapeutic dose during propofol anesthesia. Ten dogs were chronically instrumented for the measurements of systemic and coronary hemodynamics. The dogs were assigned to receive propofol with vehicle or dantrolene in a random manner on separate experimental days. Propofol significantly decreased mean arterial blood pressure, left ventricular systolic and end-diastolic pressure, the maximal rate of increase in left ventricular pressure, and left ventricular regional segment shortening. Coronary blood flow (CBF) was unchanged but coronary vascular resistance (CVR) decreased. Dantrolene reversed the decrease in mean arterial blood pressure and left ventricular systolic pressure caused by propofol, and significantly increased heart rate. However, left ventricular end-diastolic pressure, cardiac output, maximal rate of increase in left ventricular pressure, and segment shortening were unchanged. CBF was significantly increased with a decrease in CVR. These results suggest that dantrolene reverses the hypotensive action produced by propofol and causes an increase in CBF with a decrease in CVR, but does not significantly change the negative inotropic effects. Thus, dantrolene exerts favorable hemodynamic effects during propofol anesthesia.


CONCLUSIONS
Our study suggests that dantrolene reverses the hypotensive action produced by propofol and causes an increase in coronary blood flow with a decrease in coronary vascular resistance, but does not significantly change the negative inotropic effects.
Cho
Sungsam
S
Department of Anesthesiology, Nagasaki University School of Medicine, Nagasaki, Japan.
Zhang
Shiping
S
Ureshino
Hiroyuki
H
Hara
Tetsuya
T
Tomiyasu
Shiro
S
Sumikawa
Koji
K
D018686:Anesthetics, Intravenous / Q000494:pharmacology*; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects; D003620:Dantrolene / Q000494:pharmacology*; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D008297:Male; D009125:Muscle Relaxants, Central / Q000494:pharmacology*; D015742:Propofol / Q000494:pharmacology*; D013318:Stroke Volume / Q000187:drug effects; D014655:Vascular Resistance; D016277:Ventricular Function, Left / Q000187:drug effects
D018686:Anesthetics, Intravenous; D009125:Muscle Relaxants, Central; D003620:Dantrolene; D015742:Propofol